Revance Therapeutics reported $-83993000 in Pre-Tax Profit for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
ALKERMES ALKS:US USD 136K 7.25M
Cara Therapeutics CARA:US USD -23180000 18.97M
Coherus Biosciences CHRS:US USD -86650000 36.5M
Horizon Pharma HZNP:US USD 315.1M 27.58M
Johnson & Johnson JNJ:US USD 7.42B 655M
Neurocrine Biosciences NBIX:US USD 97.9M 121.2M
Revance Therapeutics RVNC:US USD -83993000 22.56M
Supernus Pharmaceuticals SUPN:US USD -444000 11.77M
Teva Pharmaceutical Industries TEVA:US USD 769M 62M